GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...
The Cardiology Advisor

AAN: GLP-1 Receptor Agonist Initiation for Chronic Migraine Tied to Improved Outcomes

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Studies explore: GLP-1 receptor agonist use and its impact on long-term musculoskeletal health and orthopaedic surgical outcomes

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...
The Cardiology Advisor

GLP-1 Receptor Agonist Use Linked to Reduced Risks for Substance Use Disorder

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Twenty percent of eligible youth prescribed GLP-1 receptor agonists

Twenty percent of potentially eligible youth are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with the ...
Endocrinology Advisor

2018 to 2025 Saw Rise in GLP-1 Receptor Agonist Rx for Bariatric Surgery-Eligible Patients

Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
Rheumatology Advisor

Weight Regain Seen After Cessation of GLP-1 Receptor Agonists in Adults With Overweight, Obesity

Adults with overweight or obesity regained most weight lost during GLP-1 receptor agonist treatment at 1 year following cessation.